NCT06049212View on ClinicalTrials.gov

Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 26, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

January 29, 2027

Conditions
Non-small Cell Lung CancerSolid TumorsProgrammed Cell Death-1 (PD1, PD-1)Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)
Interventions
BIOLOGICAL

Sacituzumab tirumotecan

Sacituzumab tirumotecan injection powder for intravenous (IV) infusion.

BIOLOGICAL

Pembrolizumab

Pembrolizumab solution for IV infusion.

DRUG

Supportive care measures

Participants are allowed to take supportive care measures at the discretion of the investigator. Prophylactic supportive care measures may include but are not limited to antiemetic agents, antidiarrheal agents, granulocyte and erythroid growth factors, and blood transfusions

Trial Locations (7)

464-8681

ACTIVE_NOT_RECRUITING

Aichi Cancer Center ( Site 0006), Nagoya

277-8577

RECRUITING

National Cancer Center Hospital East ( Site 0002), Kashiwa

791-0280

COMPLETED

National Hospital Organization Shikoku Cancer Center ( Site 0008), Matsuyama

241-8515

COMPLETED

Kanagawa Cancer Center ( Site 0004), Yokohama

573-1191

ACTIVE_NOT_RECRUITING

Kansai Medical University Hospital ( Site 0007), Hirakata

411-8777

ACTIVE_NOT_RECRUITING

Shizuoka Cancer Center ( Site 0005), Nagaizumi-cho,Sunto-gun

104-0045

RECRUITING

National Cancer Center Hospital ( Site 0001), Chuo-ku

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY